Showcases Stock ranks

Banco Santander (SAN)
2.46 -0.19 (-7.17%) 03-27 16:02
Open: 2.5 Pre. Close: 2.65
High: 2.56 Low: 2.45
Volume: 9,744,468 Market Cap: 41276M
Banco Santander SA is a global bank engaged in retail banking. The firm also offers other services such as wholesale banking, insurance and asset management. Its business operations are spread across Latin America, Continental Europe, and the U.S.
Share on Facebook   Tweet this page
Price Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 2.562 - 2.575 2.575 - 2.583
Low: 2.42 - 2.437 2.437 - 2.447
Close: 2.436 - 2.461 2.461 - 2.477
Stock Technical Analysis
Target: Six months: 3.72
One year: 4.54
Support: Support1: 2.04
Support2: 1.70
Resistance: Resistance1: 3.18
Resistance2: 3.89
Pivot: 2.53
Moving Averages: MA(5): 2.49
MA(20): 2.78
MA(100): 3.77
MA(250): 4.13
MACD: MACD(12,26): -0.34
Signal(12,26,9): -0.38
%K %D: %K(14,3): 40.57
%D(3): 34.62
RSI: RSI(14): 37.58
52-Week: High: 5.25
Low: 2.04
Change(%): -48.8
Average Vol(K): 3-Month: 1158246
10-Days: 1219264
Price, MAs and Bollinger Bands
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.

SAN has closed above bottom band by 44.4%. Bollinger Bands are 89.6% wider than normal. The large width of the bands suggest high volatility as compared to SAN's normal range. The bands have been in this wide range for 22 bars. This is a sign that the current trend might continue.
Stock chart
Stock News
2 Biotech Giants in the Hunt for New Coronavirus Drugs
With the number of confirmed COVID-19 cases rising despite worldwide lockdowns and social distancing efforts, the biotech industry is taking action. In just two months since the first infection was reported in the U.S., the country’s total number of cases has surpassed both that of Italy and China, and the Trump administration is calling on names in the space to step in. The sector’s response? Challenge accepted. As the U.S. government pumped $8.3 billion into research as well as prevention efforts, several biotech companies have joined the fight against COVID-19. Among those battling the virus, one of TipRanks’ top five rated investing firms , Oppenheimer, recently highlighted two biotech heavyweights that have made notable strides in developing COVID-19 drugs. Bearing this in mind, we used TipRanks’ database to learn more about Oppenheimer’s picks. It turns out that each Buy-rated ticker has also received substantial support from other Wall Street analysts. Here’s the full rundown. Gilead Sciences ( GILD ) First up we have healthcare giant Gilead Sciences.

Escobar: Why Is France Hiding A Cheap And Tested Virus Cure?
Escobar: Why Is France Hiding A Cheap And Tested Virus Cure? Authored by Pepe Escobar via The Asia Times, The French government is arguably helping Big Pharma profit from the Covid-19 pandemic… What’s going on in the fifth largest economy in the world arguably points to a major collusion scandal in which the French government is helping Big Pharma to profit from the expansion of Covid-19. Informed French citizens are absolutely furious about it. My initial question to a serious, unimpeachable Paris source, jurist Valerie Bugault, was about the liaisons dangereuses between Macronism and Big Pharma and especially about the mysterious “disappearance” – more likely outright theft – of all the stocks of chloroquine in possession of the French government. Respected Professor Christian Perronne talked about the theft live in one of France’s 24/7 info channels: “The central pharmacy for the hospitals announced today that they were facing a total rupture of stocks, that they were pillaged.” With input from another, anonymous source, it’s now possible to establish a timeline that puts in much-needed perspective the recent actions of the French government.

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  New York Stock Exchange
Sector:  Financial Services
Industry:  Banks - Global
Shares Out. (M) 16620.00
Shares Float (M) 16430.00
% Held by Insiders
% Held by Institutions 1.92
Shares Short (K) 9600
Shares Short Prior Month (K)
Stock Financials
EPS 0.482
Book Value (p.s.) 6.860
PEG Ratio
Profit Margin 15.92
Operating Margin
Return on Assets (ttm) 0.5
Return on Equity (ttm) 7.4
Qtrly Rev. Growth 8.0
Gross Profit (p.s.) 2.463
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth 34.60
Operating Cash Flow (M)
Levered Free Cash Flow (M)
Stock Valuation
P/E 5.10
P/E Growth Ratio -0.07
P/BV 0.36
Dividend Yield 0.09
Dividends & Splits
Dividend 0.220
Dividend Pay Date 2019-11-07
Ex-Dividend Date 2019-10-29
Forward Dividend 0.300
Last Split Date 2012-01-10
Last Split Ratio

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator